Here are the 10-Q quarterly reports from Scribe Therapeutics Inc. (SCTX) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow SCTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SCTX filings page.
Scribe Therapeutics, Inc. (SCTX) reported that for the six months ended June 30, 2026 it generated $4.2 million in collaboration revenue, down sharply from $22.0 million a year earlier, and recorded a net loss of $23.8 million versus $13.3 million in the prior-year period.
Total operating expenses declined, with research and development falling to $20.1 million and general and administrative to $5.8 million, but lower collaboration revenue and fair-value changes on a convertible note increased overall losses. Cash, cash equivalents and investments were $43.0 million at June 30, 2026, before financing events.
Subsequent to quarter-end, Scribe completed an IPO and a concurrent private placement, raising approximately $140.7 million in net proceeds, and now expects its capital to fund operations into the first half of 2029. The company also secured up to $25.7 million in multi‑year CIRM grants to support its cardiometabolic gene-editing programs STX‑1200 and STX‑1400.